Ibio Inc (IBIO) has disclosed a new risk, in the Trade Secrets category.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ibio Inc faces significant business risks due to its reliance on intellectual property licensed from third parties, particularly concerning its advanced product candidates, IBIO-600 and IBIO-610. These dependencies are tied to exclusive agreements with AstralBio, which grant Ibio Inc the rights to develop and commercialize these candidates. The termination of these licenses could lead to the loss of critical rights, adversely affecting the company’s ability to bring these products to market. Additionally, disputes over intellectual property or failure by licensors to enforce patents could further jeopardize Ibio Inc’s operations and financial health.
Overall, Wall Street has a Moderate Buy consensus rating on IBIO stock based on 2 Buys.
To learn more about Ibio Inc’s risk factors, click here.